Analysts Offer Predictions for MLYS Q2 Earnings

Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) - Equities research analysts at Lifesci Capital issued their Q2 2025 earnings estimates for shares of Mineralys Therapeutics in a research note issued on Tuesday, June 17th. Lifesci Capital analyst R. Katkhuda forecasts that the company will post earnings per share of ($0.81) for the quarter. The consensus estimate for Mineralys Therapeutics' current full-year earnings is ($4.23) per share. Lifesci Capital also issued estimates for Mineralys Therapeutics' Q3 2025 earnings at ($0.83) EPS, Q4 2025 earnings at ($0.87) EPS and FY2025 earnings at ($2.88) EPS.

A number of other research analysts have also recently issued reports on the stock. Wall Street Zen cut shares of Mineralys Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, June 14th. HC Wainwright reissued a "buy" rating and set a $42.00 price target on shares of Mineralys Therapeutics in a research report on Tuesday, June 17th. Jefferies Financial Group assumed coverage on shares of Mineralys Therapeutics in a research report on Tuesday, June 10th. They set a "hold" rating and a $15.00 price target for the company. Finally, Guggenheim set a $48.00 target price on shares of Mineralys Therapeutics and gave the stock a "buy" rating in a report on Wednesday, May 14th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, Mineralys Therapeutics presently has an average rating of "Hold" and an average price target of $32.25.

Mineralys Therapeutics Price Performance

NASDAQ MLYS traded down $0.25 during trading hours on Thursday, reaching $13.48. 2,899,241 shares of the company's stock traded hands, compared to its average volume of 530,943. Mineralys Therapeutics has a 52-week low of $8.24 and a 52-week high of $18.38. The firm has a market cap of $878.63 million, a PE ratio of -3.61 and a beta of -0.17. The firm has a 50-day simple moving average of $14.84 and a 200 day simple moving average of $12.87.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($0.79) earnings per share for the quarter, beating analysts' consensus estimates of ($1.02) by $0.23.

Insiders Place Their Bets

In related news, CEO Jon Congleton sold 15,319 shares of the company's stock in a transaction on Friday, April 11th. The shares were sold at an average price of $12.19, for a total transaction of $186,738.61. Following the completion of the transaction, the chief executive officer now owns 862,289 shares in the company, valued at approximately $10,511,302.91. This represents a 1.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider David Malcom Rodman sold 11,366 shares of the company's stock in a transaction on Wednesday, May 14th. The stock was sold at an average price of $15.29, for a total transaction of $173,786.14. Following the transaction, the insider now owns 106,669 shares of the company's stock, valued at approximately $1,630,969.01. This represents a 9.63% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 104,579 shares of company stock worth $1,534,353 over the last three months. 25.56% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Mineralys Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of MLYS. RA Capital Management L.P. boosted its position in shares of Mineralys Therapeutics by 26.7% during the first quarter. RA Capital Management L.P. now owns 6,147,280 shares of the company's stock worth $97,619,000 after acquiring an additional 1,296,296 shares during the last quarter. SR One Capital Management LP raised its stake in Mineralys Therapeutics by 55.1% during the first quarter. SR One Capital Management LP now owns 3,127,933 shares of the company's stock valued at $49,672,000 after purchasing an additional 1,111,111 shares in the last quarter. Millennium Management LLC raised its stake in Mineralys Therapeutics by 1,015.8% during the fourth quarter. Millennium Management LLC now owns 1,101,674 shares of the company's stock valued at $13,562,000 after purchasing an additional 1,002,941 shares in the last quarter. Jennison Associates LLC raised its stake in Mineralys Therapeutics by 82.9% during the first quarter. Jennison Associates LLC now owns 1,979,033 shares of the company's stock valued at $31,427,000 after purchasing an additional 897,027 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in Mineralys Therapeutics by 42.1% during the first quarter. Vanguard Group Inc. now owns 2,035,506 shares of the company's stock valued at $32,324,000 after purchasing an additional 603,464 shares in the last quarter. Institutional investors own 84.46% of the company's stock.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.